Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CMRX

Chimerix (CMRX) Stock Price, News & Analysis

Chimerix logo

About Chimerix Stock (NASDAQ:CMRX)

Advanced Chart

Key Stats

Today's Range
$8.54
$8.54
50-Day Range
$8.54
$8.54
52-Week Range
$0.75
$8.55
Volume
N/A
Average Volume
2.90 million shs
Market Capitalization
$801.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.53
Consensus Rating
Hold

Company Overview

Chimerix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

CMRX MarketRank™: 

Chimerix scored higher than 11% of companies evaluated by MarketBeat, and ranked 893rd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Chimerix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Chimerix has received no research coverage in the past 90 days.

  • Read more about Chimerix's stock forecast and price target.
  • Earnings Growth

    Earnings for Chimerix are expected to grow in the coming year, from ($0.99) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Chimerix has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Chimerix's valuation and earnings.
  • Short Interest

    There is no current short interest data available for CMRX.
  • Dividend Yield

    Chimerix does not currently pay a dividend.

  • Dividend Growth

    Chimerix does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CMRX.
  • Search Interest

    Only 1 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Chimerix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Chimerix's insider trading history.
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

CMRX Stock News Headlines

AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
Chimerix reports Q4 EPS (25c), consensus (28c)
See More Headlines

CMRX Stock Analysis - Frequently Asked Questions

Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings data on Friday, March, 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.31 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), Pfizer (PFE) and Broadcom (AVGO).

Company Calendar

Last Earnings
3/21/2025
Today
7/18/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CMRX
CIK
1117480
Employees
90
Year Founded
2000

Price Target and Rating

High Price Target
$8.55
Low Price Target
$8.50
Potential Upside/Downside
-0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.99)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$82.10 million
Net Margins
N/A
Pretax Margin
-52,574.85%
Return on Equity
-50.78%
Return on Assets
-44.94%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.33
Quick Ratio
6.33

Sales & Book Value

Annual Sales
$212 thousand
Price / Sales
3,778.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.17 per share
Price / Book
3.94

Miscellaneous

Outstanding Shares
93,804,000
Free Float
78,154,000
Market Cap
$801.09 million
Optionable
Optionable
Beta
-0.17

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CMRX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners